SEARCH

SEARCH BY CITATION

References

  • 1
    Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 40935.
  • 2
    Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 110618.
  • 3
    Debril MB, Renaud JP, Fajas L, Auwerx J. The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J Mol Med 2001; 79: 3047.
  • 4
    Kopelovich L, Fay JR, Glazer RI, Crowell JA. Peroxisome proliferator-activate receptor modulators as potential chemopreventive agents. Mol Cancer Therap 2002; 1: 135763.
  • 5
    Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nature Rev Cancer 2004; 4: 6170.
  • 6
    Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncology 2004; 5: 41929.
  • 7
    Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miypshi I, Koeffler HP. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effects against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 334452.
  • 8
    Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, Sporn MB. A new ligand for the peroxisome proliferators-activator receptor-γ (PPAR-γ) GW7845 inhibits rat mammary carcinogenesis. Cancer Res 1999; 59: 56713.
  • 9
    Auwerx J. Nuclear receptors I. PPAR-γ in the gastrointestinal tract: gain or pain? Am J Physiol Gastrointest Liver Physiol 2002; 282: G5815.
  • 10
    Gupta RA, DuBois RN. Controversy: PPAR-γ as a target for treatment of colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2002; 283:G 2669.
  • 11
    Koeffler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res 2003; 9: 19.
  • 12
    Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden. SA, Chen LB, Singer S, Fletcher C, Spiegelman BM. Differentiation and reversal of malignant changes in colon cancer through PPAR-γ. Nature Med 1998; 4: 104652.
  • 13
    Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsuhashi N, Kadowaki T, Ochiai M, Sekihara H, Nakagama H. Peroxisome proliferators-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003; 124: 3617.
  • 14
    Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, Eng C, Nambiar P, Rosenberg DW, Bronson RT, Edelmann W, Kucherlapati R, Gonzalez FJ, et al. APC-dependent suppression of colon carcinogenesis by PPARγ. Proc Natl Acad Sci U S A 2002; 99: 137716.
  • 15
    Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J. Activation of the peroxisome proliferators-activated receptor ã promotes the development of colon tumors in C57BL/6J-APCMin /+ mice. Nature Med 1998; 4: 10537.
  • 16
    Saez. E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nature Med 1998; 4: 105861.
  • 17
    Pino MV, Kelley MF, Jayyosi Z. Promotion of colon tumors in C57BL/6J-APCMin/+ mice by thiazolidinedione PPARγ agonists and a structurally unrelated PPAR-γ agonist. Toxicol Pathol 2004; 32: 5863.
  • 18
    Edelmann W, Yang K, Kuraguchi M, Heyer J, Lia M, Kneitz B, Fan K, Brown AM, Lipkin M, Kucherlapati R. Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice. Cancer Res 1999; 59: 13017.
  • 19
    Jass JR, Sobin KH. Histological, typing of intestinal tumors, 2nd ed. World Health Organization. Berlin: Springler-Verlag, 1989.
  • 20
    Yang K, Edelmann W, Fan K, Lau K, Kolli VR, Fodde R, Meera Khan M, Kucherlapati R, Lipkin M. A mouse model of human familial adenomatous polyposis. J Exp Zool 1997; 277: 24554.
  • 21
    Lamprecht S A, Lipkin M. Mouse models of gastrointestinal tumorigenesis for dietary cancer prevention studies. Nutr Rev 2003; 61: 2558.
  • 22
    Edelmann L, Edelmann W. Loss of DNA mismatch repair function and cancer predisposition in the mouse: animal models for human hereditary polyposis colorectal cancer. Am J Med Gen Part C Seminars in Medical Genetics 2004; 129: 919.
  • 23
    Corpet DE, Pierre F. Point: from animal models to prevention of colon cancer—systematic review of chemoprevention in Min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003; 12: 391400.
  • 24
    Yang K, Fan K, Kurihara N, Shinozaki H, Rigas B, Augentlicht L, Kopelovich L, Edelmann W, Kucherlapati R, Lipkin M. Regional responses leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations. Carcinogenesis 2003; 24: 60511.
  • 25
    Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nature Med 2004; 10: 2457.
  • 26
    Newmark, H L, Yang K, Lipkin M, Kopelovich L, Liu Y, Fan K, Shinozaki H. A Western-style diet induces benign and malignant neoplasms in the colon of normal C57Bl/6 mice. Carcinogenesis 2001; 22: 18715.
  • 27
    Hurlstone DP, Cross SS, Adam I, Shorthouse AJ, Brown S, Sanders DS, Lobo AJ. A prospective and clinicopathological and endoscopic evaluation of flat and depressed colorectal lesions in the United Kingdom. Am J Gastroenterol 2003; 98: 25439.
    Direct Link:
  • 28
    van Wyk R, Slezak P, Kotze MJ, Jaramillo E, Koizumi K, Grobbelaar JJ. Multiple APC mutations in sporadic flat colorectal adenomas. Eur Human Gen 1999; 7: 92832.
  • 29
    Bartkova J, Thullberg M, Slezak P, Jaramillo E, Rubio C, Thomassen LH, Bartek J. Aberrant expression of G1-phase cell cycle regulators in flat and exophytic adenomas of the human colon. Gastroenterology 2001; 120: 16808.
  • 30
    Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, Banayo E, Cardiff RD, Izpisua-Belmonte JC, Evans RM. PPARγ signaling exacerbates mammary gland tumor development. Genes Dev 2004; 18: 52840.
  • 31
    Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653: 124.
  • 32
    Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, Speizer FE, Giovannucci E. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Nat Cancer Inst. 1999: 91; 5427.
  • 33
    Khaw K-T, Wareham N, Bingham S, Luben R, Welch A, Day N. Preliminary communication: Glycated hemoglobin, diabetes and incident colorectal cancer in man and women: a prospective analysis from the European Prospectiv Investigation into Cancer-Norfolk Study. Cancer Epidemiol Biomarkers Prev 2004; 13: 9159.
  • 34
    Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Rev Cancer 2004; 4: 57991.
  • 35
    Niho N, Takahashi M, Kitamura T, Itoh M, Noda T, Shoji Y, Sugimura T, Wakabayashi K. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands Cancer Res 2003; 63: 60905.
  • 36
    Niho N, Tahahashi M, Shoji Y, Takeucki Y, Matsubara S, Sugimara T, Wakabayashi K. Dose-dependent suppression of hyperlipidemias and intestinal polyp formation in Min mice by pioglitazone, a PPAR-γ ligand. Cancer Sci 2003; 94: 9604.
  • 37
    Nicol CJ, Yoon M, Ward JM, Yamashita M, Fukamachi K, Peters JM, Gonzales FJ. PPARγ influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 2004; 25: 174755.